SER icon

Serina Therapeutics

6.31 USD
+0.53
9.17%
At close Apr 30, 4:00 PM EDT
After hours
6.48
+0.17
2.69%
1 day
9.17%
5 days
5.34%
1 month
11.29%
3 months
37.17%
6 months
-6.66%
Year to date
23.73%
1 year
-23.98%
5 years
-78.75%
10 years
-93.38%
 

About: Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Employees: 13

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

4% more funds holding

Funds holding: 24 [Q3] → 25 (+1) [Q4]

0.21% more ownership

Funds ownership: 3.38% [Q3] → 3.59% (+0.21%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

20% less capital invested

Capital invested by funds: $2.01M [Q3] → $1.6M (-$408K) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
74%
upside
Avg. target
$11
74%
upside
High target
$11
74%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Jones Trading
Justin Walsh
27% 1-year accuracy
3 / 11 met price target
74%upside
$11
Buy
Initiated
11 Mar 2025

Financial journalist opinion

Based on 4 articles about SER published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
Neutral
GlobeNewsWire
2 weeks ago
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG Dilemma – A Solution," will take place on Tuesday, April 15, at 9:30 AM ET. The session will focus on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics and introduces Serina's POZ-lipid technology as an immune-silent alternative to PEG-lipids.
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
Neutral
GlobeNewsWire
3 weeks ago
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
Neutral
GlobeNewsWire
3 weeks ago
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3:00 p.m. PDT.
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights.
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology.
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Neutral
GlobeNewsWire
2 months ago
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Neutral
GlobeNewsWire
2 months ago
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. The closing represented the second tranche of the $10 million total financing announced on December 2, 2024.
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
Neutral
GlobeNewsWire
3 months ago
Serina Therapeutics Announces Sale of UniverXome Subsidiary
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025.
Serina Therapeutics Announces Sale of UniverXome Subsidiary
Neutral
GlobeNewsWire
3 months ago
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors.
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
Charts implemented using Lightweight Charts™